[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@MonkofFinance Avatar @MonkofFinance Finance News Monk 📈

Finance News Monk 📈 posts on X about $phge, marks, finance the most. They currently have XXX followers and XXX posts still getting attention that total X engagements in the last XX hours.

Engagements: undefined #

Engagements Line Chart

Mentions: undefined #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence #

Social category influence exchanges

Social topic influence $phge, marks, finance

Top Social Posts #

Top posts by engagements in the last XX hours

"$PHGE BiomX Inc. (NYSE: PHGE) has initiated patient dosing in its Phase 2b trial for BX004 a phage therapy targeting lung infections in cystic fibrosis patients. According to the announcement this milestone has prompted H.C. Wainwright to reiterate its Buy rating and $XX price target. The Phase 2b trial is evaluating BX004 in approximately XX patients over X weeks with topline results expected in Q1 2026. Previous trials have shown promising efficacy with some patients achieving complete clearance of chronic Pseudomonas aeruginosa infections. H.C. Wainwright's valuation model equally weighs"
@MonkofFinance Avatar @MonkofFinance on X 2025-07-18 17:34:57 UTC XXX followers, XX engagements

"$PHGE BiomX has initiated its Phase 2b trial for BX004 a phage therapy targeting antibiotic-resistant lung infections in Cystic Fibrosis patients. According to the announcement the first patient has been dosed marking a significant milestone. Topline results are expected in Q1 2026. The Phase 2b trial is a randomized double-blind placebo-controlled study evaluating BX004 in approximately XX CF patients with chronic P. aeruginosa infections. It builds upon Phase 1b/2a results that demonstrated complete bacterial clearance in XXXX% of patients after XX days. BiomX anticipates FDA feedback in H2"
@MonkofFinance Avatar @MonkofFinance on X 2025-07-14 13:21:30 UTC XXX followers, XX engagements

"$PHGE BiomX (NYSE: PHGE) has initiated its Phase 2b trial for BX004 a phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients. According to the announcement this marks a significant step in addressing antibiotic-resistant infections. Earlier Phase 1b/2a trial results showed promising outcomes with XXXX% of patients achieving complete bacterial clearance after XX days including one patient with a 35-year infection. The FDA has granted BX004 Fast Track and Orphan Drug designations. Regulatory feedback is expected in the second half of 2025. BiomX's pipeline extends beyond"
@MonkofFinance Avatar @MonkofFinance on X 2025-07-14 13:55:30 UTC XXX followers, XXX engagements